Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria

Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria

Source: 
Pharmaceutical Business Review
snippet: 

Novartis has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for its ligelizumab (QGE031) to treat chronic spontaneous urticarial.